|1.||Lau, Yuen-Sum: 5 articles (11/2011 - 12/2007)|
|2.||Patel, Pankaj A: 4 articles (07/2009 - 04/2006)|
|3.||Manivasagam, Thamilarasan: 3 articles (10/2014 - 01/2012)|
|4.||Essa, Musthafa Mohamed: 3 articles (10/2014 - 01/2012)|
|5.||Dahl, Gerhard: 3 articles (01/2013 - 09/2008)|
|6.||Mody, Reema R: 3 articles (07/2009 - 03/2008)|
|7.||Sung, Yun-Hee: 2 articles (10/2015 - 12/2012)|
|8.||Wu, Eric Q: 2 articles (08/2015 - 03/2008)|
|9.||Löscher, Wolfgang: 2 articles (01/2015 - 07/2003)|
|10.||Toldi, József: 2 articles (01/2015 - 09/2009)|
09/01/1982 - "In comparison, APPG-probenecid eradicated 125 (98.4%) of 127 urethral or endocervical gonococcal infections, 17 (94%) of 18 rectal infections, and 4 (100%) of 4 pharyngeal infections. "
04/01/2014 - "These findings suggest neuronal pyroptosis is an important cell death mechanism during CNS infection and injury that may be attenuated by probenecid. "
07/01/2014 - "In this study, we demonstrate that probenecid reduces infection and inflammation in acute P. "
01/01/2013 - "As the inflammasome has been implicated in the progression of Chlamydia infections, and with chlamydial infections at record levels in the US, we therefore investigated whether probenecid would have a direct effect on Chlamydia trachomatis development through inhibition of Panx1. "
01/01/2013 - "Probenecid, a prototypical uricosuric agent and chemical inhibitor of organic anion transporters known to target OAT3, was shown to be effective in limiting influenza A virus infection in vitro (50% inhibitory concentration [IC(50)] of 5.0 × 10(-5) to 5.0 × 10(-4) μM; P < 0.005) and in vivo (P < 0.05). "
12/01/1983 - "MICs of PCG to the 12 PPNG strains were 3.13 - 25 micrograms/ml and to the 68 non-PPNG strains were 0.0122 - 3.13 micrograms/ml. While MICs of CZX to the PPNG strains were less than or equal to 0.003 - 0.024 micrograms/ml and to the non-PPNG strains were less than or equal to 0.003 - 0.05 micrograms/ml. Those patients with gonorrheal urethritis were given a single 0.5 g intramuscular dose of CZX and a single 1 g oral dose of probenecid. "
08/18/1990 - "The therapeutic efficacy of single intramuscular doses of ceftriaxone (Rocephin; Roche) (62.5, 125 and 250 mg), administered without probenecid, was evaluated in 167 adult males with uncomplicated acute gonococcal urethritis. "
12/01/1997 - "The trial demonstrated the efficacy of a single oral dose of cefaclor with probenecid for the treatment of uncomplicated gonococcal urethritis in South Africa. "
05/01/1985 - "[Treatment of gonorrheal urethritis with a single dose of penicillin in combination with probenecid]."
02/01/1984 - "Young men with uncomplicated gonococcal urethritis were treated with 1 gram of cefonicid given intramuscularly plus 1 gram of probenecid by mouth. "
04/01/1989 - "Therefore, the combination of epiciline-probenecid is a valid alternative for routine treatment of acute uncomplicated gonorrhea."
04/01/1989 - "We treated 142 patients with acute uncomplicated gonorrhea with a single oral dose of epiciline-probenecid. "
09/05/1968 - "[Gonorrhea therapy with a combination of probenecid and benzylsodiumpenicillin. "
08/01/1986 - "Cefuroxime axetil alone is effective for urethral gonorrhea in males; rectal gonorrhea probably requires additional probenecid."
02/01/1980 - "The data suggest a possible means by which probenecid improves the efficacy of gonorrhea therapy with aqueous procaine penicillin G. "
03/15/1985 - "These observations may provide an additional explanation for probenecid enhancement of the therapeutic efficacy of MTX in tumor bearing mice and highlight the importance of assessing drug-protein interactions in an in vitro experimental model."
02/01/2012 - "Probenecid is a chemosensitizer in cancer cell lines."
05/01/2010 - "Probenecid did not increase the exposure of MTX inside the tumor, but caused a longer half-life of central MTX. "
04/27/2001 - "Altogether, MRP inhibitors such as probenecid have been shown to function as a double-edged sword, indicating that they are not only an effective chemosensitizer of MRP-associated MDR tumor cells but also an MRP activator. "
01/01/1997 - "These results suggest that probenecid is an effective chemosensitizer of MRP-associated MDR tumor cells and is a potential candidate for clinical use to reverse MDR."
|5.||Cystic Fibrosis (Mucoviscidosis)
01/01/1991 - "Probenecid pharmacokinetics were studied in 5 cystic fibrosis (CF) subjects and 5 control subjects at oral dosages of 5, 15, and 30 mg/kg. Serum and urine samples were collected for 8 h after administration and assayed by reverse phase high performance liquid chromatography. "
01/01/1991 - "Probenecid pharmacokinetics in cystic fibrosis."
08/01/2008 - "Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine."
08/01/2008 - "Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day. "
08/01/2008 - "No difference in fexofenadine pharmacokinetic parameters was observed between cystic fibrosis patients and healthy volunteers when fexofenadine was administered with or without probenecid. "
|4.||Penicillin G Procaine (Procaine, Benzylpenicillin)
|5.||cefuroxime axetil (Ceftin)